A hearing held on December 4, 2015 resulted in the Judicial Panel concluding
a multi-district litigation was in order to more efficiently take care
of the more than 2,800 Xarelto cases that have been filed against Bayer
AG and Janssen Pharmaceuticals. MDL consolidation results in faster litigation,
as discovery issues are facilitated and conflicting rulings by multiple
pre-trial drugs are eliminated. Litigation costs, as well as the time
it takes to go through the trial process, are significantly lessened among
those involved in the Xarelto cases when they are consolidated. This particular
Xarelto MDL—number 2592—will be heard by the Honorable U.S.
District Judge Eldon E. Fallon, who, according to all accounts, is very
comfortable with MDL litigation, and will be able to provide the proper
leadership in these cases.
Bayer AG and Janssen Pharmaceuticals Resist Xarelto MDL
The defendants in the Xarelto cases, Bayer AG and Janssen Pharmaceuticals
(a subsidiary of Johnson & Johnson), resisted the MDL consolidation
in Illinois, as both companies are located in New Jersey. Many Xarelto
patients claim they have suffered uncontrollable bleeding episodes after
taking the drug. A comparable drug, Pradaxa, shares many similarities
with Xarelto. Pradaxa was the subject of more than 3,500 adverse event
reports, with 750 fatalities, and the focus of more than 4,000 lawsuits.
Rather than go to trial, Pradaxa’s manufacturer, Boehringer Ingelheim,
made the decision to settle all the lawsuits for $650 million. Of course
many Xarelto plaintiffs are hoping Janssen and Bayer AG will do the same.
Currently, however, the MDL cases are progressing toward litigation. Judge
Fallon gave a deadline of January 11, 2016, for 40 cases to be selected
from those filed. From those 40 cases, four cases will be chosen and prepared
for bellwether trials. The first Xarelto bellwether trial is expected
to begin on February 6 and March 13, 2017. In addition to MDL 2592,there
is currently another group of more than 550 Xarelto plaintiffs, which
were consolidated into a mass tort program in Philadelphia.
What is Xarelto and What are the Dangers of Xarelto?
Xarelto is an anticoagulant, widely prescribed to prevent blood clots in
those who suffer from atrial fibrillation, deep vein thrombosis, pulmonary
embolism, stroke, and for those who have recently undergone knee or hip
replacement surgery. Xarelto is prescribed in place of the older blood-thinning
drug, Warfarin, which has been in use since 1954. The manufacturers of
Xarelto and Pradaxa touted the advantages of the drugs to consumers and
doctors, namely no regular blood monitoring required and no known interactions
to foods, drinks or other medications.
did not make widely known to consumers or doctors is that while Warfarin has an
antidote—Vitamin K—in the case of a severe bleed, there is
no known antidote to Xarelto. The Xarelto cases currently filed claim
that if patients and doctors had been aware of the risk of uncontrolled
bleeding while taking the drug, they would have opted to take Warfarin instead.
Further Complications from Xarelto
In addition to uncontrolled bleeding, potential Xarelto side effects include
decreased hemoglobin, cerebrovascular accidents, hematomas, swelling of
the lower limbs and difficulty breathing. Patients taking Xarelto are
cautioned to avoid any activity which could result in cuts or bruises.
If such an injury does occur—particularly if accompanied by persistent
bleeding confusion, dizziness, swelling, changes in vision or severe headaches—it
is imperative that medical help be sought immediately.
No Recall of Xarelto in Sight
There is currently no recall of the drug Xarelto, although the FDA is looking
into questions as to whether faulty equipment was used to monitor at least
some of the patients in the Xarelto clinical trial, making the drug appear
superior to Warfarin. The lead researcher of the potentially tainted study
has now been nominated by President Obama to head up the FDA. Those who
have suffered injuries as a result of taking Xarelto should speak to an
experienced Pennsylvania personal injury attorney who can answer any questions
and ensure your rights are protected.
National Dangerous Drug Lawyers
If you have suffered medical complications, pain, or excessive bleeding
after using Xarelto, your injuries may be the result of a drug manufacturer's
negligence. To learn more about your legal options or to schedule a free
consultation call the Philadelphia class action lawyers at Golomb &
Honik, P.C. today at
(215) 278-4449, or fill out our
online case evaluation form. Our firm represents injured individuals in Pennsylvania, New Jersey,
and throughout the country.